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In addition to the known effects on drug metabolism and response, functional polymor-
phisms of genes coding for xenobiotic-metabolizing enzymes (XME) play a role in cancer.
Genes coding for XME act as low-penetrance genes and confer modest but consistent
and significant risks for a variety of cancers related to the interaction of environmental and
genetic factors. Consistent evidence supports a role for polymorphisms of the cytochrome
P450 CYP2C9 gene as a protecting factor for colorectal cancer susceptibility. It has been
shown that CYP2C8 and CYP2C9 overlap in substrate specificity. Because CYP2C8 has
the common functional polymorphisms rs11572080 and rs10509681 (CYP2C8∗3), it could
be speculated that part of the findings attributed to CYP2C9 polymorphisms may actually
be related to the presence of polymorphisms in the CYP2C8 gene. Nevertheless, little
attention has been paid to the role of the CYP2C8 polymorphism in colorectal cancer. We
analyzed the influence of the CYP2C8∗3 allele in the risk of developing colorectal cancer
in genomic DNA from 153 individuals suffering colorectal cancer and from 298 age- and
gender-matched control subjects. Our findings do not support any effect of the CYP2C8∗3
allele (OR for carriers of functional CYP2C8 alleles=0.50 (95% CI=0.16–1.59; p=0.233).
The absence of a relative risk related to CYP2C8∗3 did not vary depending on the tumor
site. We conclude that the risk of developing colorectal cancer does not seem to be related
to the commonest functional genetic variation in the CYP2C8 gene.
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INTRODUCTION
In addition to the known effects on drug metabolism and response,
functional polymorphisms of genes coding for xenobiotic-
metabolizing enzymes (XME) play a modest but consistent role
in cancer risk. Genes coding for XME act as low-penetrance genes
and confer significant risks for a variety of cancers related to the
interaction of environmental and genetic factors (Agundez, 2004).
Cytochrome P450 (CYP) enzymes are involved in the metabo-
lism of drugs and other xenobiotics. Two enzymes of the CYP2C
subfamily, CYP2C8 and CYP2C9, have received special attention
because they are involved in the metabolism of several commonly
used drugs and are capable of activating carcinogens and muta-
gens. Consistent evidence supports a role for polymorphisms
of the cytochrome P450 CYP2C9 gene that produce decreased
enzymatic activity as a protecting factor for colorectal cancer sus-
ceptibility (Martinez et al., 2001; Chan et al., 2004, 2009; Cleary
et al., 2010; Northwood et al., 2010).
One of the mechanisms proposed for this protecting effect
is based on the effect of non-steroidal anti-inflammatory drugs
(NSAIDs). Inflammation is a known risk factor for colorectal
cancer, and the use of NSAIDs constitute a potential means of
decreasing inflammation in the colonic epithelium (Ulrich et al.,
2006). For this reason, interindividual variability in the metabo-
lism of NSAIDs may play a role in colorectal cancer risk (Bosetti
et al., 2012). Two cytochrome P450 enzymes, namely CYP2C9 and,
to a lesser extent, CYP2C8, play a major role in the metabolism of
NSAIDs (for a review, see Agundez et al., 2009). CYP2C enzymes
are expressed in human colon and in colorectal cancer cells (Mar-
tinez et al., 2002; Bergheim et al., 2005b; Garcia-Martin et al.,
2006b). In addition CYP2C8 expression in colorectal cancer cells
is inducible (Garcia-Martin et al., 2006b), and it has been postu-
lated that altered expression of CYP2C enzymes might contribute
to the development of colon cancer (Bergheim et al., 2005a).
Although it is known that CYP2C9 y CYP2C8 have common
substrates including NSAIDs (Garcia-Martin et al., 2004; Mar-
tinez et al., 2005; Totah and Rettie, 2005), a putative association
between CYP2C8 polymorphisms and colorectal cancer risk has
not been analyzed in detail. Only the effect of CYP2C8 polymor-
phisms as modifying factors for the protective effect of regular
NSAID use has been analyzed (McGreavey et al., 2005). This study
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indicated a lack of association of CYP2C8 polymorphisms, but
also of CYP2C9 polymorphisms as modifiers of the protective
effect of regular NSAID use on the risk of colorectal carcinoma.
Nevertheless, the potential of CYP2C8 polymorphisms as poten-
tial modifiers of colorectal cancer risk remains to be analyzed in
detail.
In the present study we analyzed the association of CYP2C8∗3
with colorectal cancer in a Spanish population. CYP2C8 is involved
in the metabolism of arachidonic and retinoic acid. It is the main
enzyme involved in the metabolism of R-ibuprofen and it has been
shown to make a significant contribution to the metabolism of
many other NSAIDs (Martinez et al., 2006). Several variant alle-
les have been described for the CYP2C8 gene, CYP2C8∗3 being
the most common variant allele among Caucasian individuals
(Garcia-Martin et al., 2006a). The effect in vivo of this mutation
is a decrease in the metabolism and altered pharmacokinetics of
CYP2C8 substrates (Martinez et al., 2005).
MATERIALS AND METHODS
The study group consisted of 153 unrelated consecutive patients
(82 men and 71 women) with colorectal cancer, and 298 healthy
subjects (Table 1). These subjects have participated in previous
studies (Garcia-Martin et al., 2001; Martinez et al., 2001). All the
participants were white Spanish individuals, living in the same
areas as the patients (Madrid and surrounding areas), and were
included in the study after giving informed written consent. The
diagnosis was based on histology analyses of endoscopic biopsies
and/or surgical resection specimens. Data regarding known previ-
ous digestive diseases, alcohol, and tobacco consumption, serum
tests for hepatitis B and C virus and other diseases were collected.
Heavy drinkers were defined as individuals drinking more than
50 g of alcohol per day. All the patients were requested to par-
ticipate in the study, and all of them agreed to do so. Control
samples were obtained from medical students, University, and
Hospital staff. A medical examination was carried out to iden-
tify subjects in good health. Over 95% of the healthy subjects
requested agreed to participate in the study. The protocol was
approved by the Ethics Committee of the San Carlos University
Hospital, Madrid. A possible confounding factor in the present
study is that, within a study group, the frequency of individu-
als carrying a determined variant allele may change with age in
the event that the presence of such an allele would be related
to severe diseases. If a determined genotype has a “protecting
effect” against any disease, it may be expected that in popula-
tions consisting of older subjects there is an increased frequency
of such a protecting genotype. Therefore we included within the
control group a selected subgroup of 41 healthy subjects with
ages ranging from 90 to 95 years (Martinez et al., 2001). Geno-
type analysis indicates frequencies that were identical to those
of younger healthy subjects (see Results). Another possible con-
founder is related to the fact that the control subjects are highly
educated people, and differences in lifestyle as compared to can-
cer patients may be expected. Since digestive cancers are partly
related to diet, these changes in lifestyle may be relevant. However,
it should be stated that patients and controls were interviewed to
assure that diet and lifestyle did not differ between patients and
control subjects. Blood samples from all participants were stored at
−80˚C until analysis and genomic DNA was prepared from periph-
eral leukocytes. The analyses for the CYP2C8∗3 gene variants
were carried out by amplification-restriction procedures. Briefly,
the pair of primers 5′-CTTCCGTGCTACATGATGACG-3′ and
5′-CTGCTGAGAAAGGCATGAAG-3′ was used for a mismatch
PCR-RFLP test. The 117 bp PCR product was purified and digested
with the endonuclease XmnI, that produced two fragments of 92
and 25 bp in the CYP2C8∗1 allele product, and did not digest the
CYP2C8∗3 PCR product. Further details are described elsewhere
(Martinez et al., 2005). Twenty DNA samples with every genotype
(CYP2C8∗1/∗1 and ∗1/∗3) and all samples with the CYP2C8∗3/∗3
genotypes were cross-tested with TaqMan probes designed to
detect theCYP2C8∗3 variant allele (rs11572080; C__25625794_10;
Applied Biosystems, Madrid, Spain) and in all cases the genotypes
obtained by amplification-restriction and by the TaqMan analyses
fully corresponded.
STATISTICAL ANALYSIS
The intergroup comparison values were calculated using chi-
square or Fisher’s exact tests when appropriate. Logistic regression
analyses were performed using the SPSS 15.0 for Windows (SPSS
Inc., Chicago, IL, USA) to test for confounders, including gender,
age at diagnosis, smoking and drinking habits, and tumor local-
ization. The 95% confidence intervals were also calculated. The
statistical power calculated for the sample size of this study, deter-
mined from allele frequencies with a genetic model analyzing the
frequency of the risk gene with RR= 2.0; p= 0.05) for two-tailed
and one-tailed associations of the risk with the variant allele is
98.1 and 99.2%, respectively. The minimum odds ratio detectable
Table 1 | Characteristics of the individuals included in the study.
Patients Controls
Male (n=82) Female (n=71) Male (n=160) Female (n=138)
Age years (mean±SD) 66.9±9.6 65.6±12.9 65.8±10.2 66.0±11.7
Non-smokers/smokers 53/29 69/2 108/52 129/9
Non-drinkers/drinkers 60/22 71/0 141/19 138/0
TUMOR SITE
Non-sigmoid 33 22 – –
Sigmoid 26 22 – –
Rectum 23 27 – –
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with this sample size is 1.55, with a statistical power for one-tailed
association equal to 80%.
RESULTS
Table 2 shows the CYP2C8∗1/∗3 genotypes and allele frequen-
cies in colorectal cancer patients and healthy subjects. Differences
noted by the comparison of genotype frequencies among them
were not statistically significant. Odds ratio for carriers of the func-
tional CYP2C8∗1 allele= 0.50 95% C.I.= 0.160–1.59; χ2= 1.42;
p= 0.233. These findings were not influenced by gender, previous
surgical therapy, or chemotherapy and Dukes’ stage of the tumor.
Genotypes in both patients and control subjects are in Hardy–
Weinberg’s equilibrium. Deviation test from Hardy–Weinberg’s
equilibrium (Pearson): p= 0.172 (patients); p= 0.265 (controls).
Trend test with the number of variantCYP2C8∗3 alleles: p= 0.584.
To elucidate whether the CYP2C8 genotype could be related to
a particular type of colorectal cancer, patients were divided into
three subgroups according to the anatomical site of the tumor (rec-
tum, sigmoid colon, and non-sigmoid colon). Table 3 shows that
none of the intergroup comparisons or comparisons with control
subjects were significant. Deviation test from Hardy–Weinberg’s
equilibrium (Pearson): p= 0.603 (non-sigmoid); p= 0.167 (sig-
moid); p= 0.587 (rectum). Logistic regression analyses did not
indicate any influence of confounders such as gender, age at diag-
nosis, smoking and drinking habits, or tumor localization in the
negative findings obtained in this study.
DISCUSSION
The clinical use of genetic biomarkers for the identification of high
risk subpopulations is a major goal which scientists have long been
pursuing. In the case of colorectal cancer, the search for risk bio-
markers by means of genome wide association studies (GWAs)
has provided relevant information, pointing in particular to the
single nucleotide polymorphism rs3802842 at 11q23.1 and five
additional loci. When SNPs in these loci are combined, the risk
increases with an increasing number of variant alleles (Pittman
et al., 2008; Tomlinson et al., 2008). Nevertheless, the biomark-
ers identified in GWA studies explain only a minor percentage of
the risk and so these studies should be completed with additional
research.
Various candidate gene association studies (CGAs) have been
carried out in an attempt to identify low-penetrance genes capa-
ble of increasing the risk of developing colorectal cancer. With
regard to cytochrome P450 enzymes, two mechanisms have been
proposed to explain a putative association between the CYP2C9
polymorphism and colorectal cancer risk. A number of xenobi-
otics that are ingested as pyrolysis products have been related to
colorectal cancer risk. These include polycyclic aromatic hydrocar-
bons and heterocyclic aromatic amines. Several of these mutagenic
substances are CYP2C substrates (Snyderwine et al., 1997; Jonsdot-
tir et al., 2012) and therefore a genetically determined alteration
in the metabolism of carcinogens and mutagens may underlie
the observed association. This first hypothesis would imply that,
besides CYPs, polymorphisms in other enzymes involved in the
metabolism of polycyclic aromatic hydrocarbons and heterocyclic
aromatic amines would influence the risk. This hypothesis is partly
supported by the influence of NAT2 polymorphisms in colorectal
cancer risk (revised in Agundez, 2008). The second mechanism
proposed to explain the association between the CYP2C9 poly-
morphism and colorectal cancer risk is the key role that CYP2C9
plays in the metabolism of NSAIDs. This, together with the protec-
tive effect that NSAIDs play in human colorectal cancer, leads to the
theory that in individuals with high CYP2C9 enzyme activity the
protective effect of NSAIDs could be diminished. Because CYP2C8
and CYP2C9 show partial overlapping in substrate specificity, par-
ticularly related to some NSAIDs such as ibuprofen, celecoxib,
diclofenac, or tenoxicam (Tang, 2003; Garcia-Martin et al., 2004;
Martinez et al., 2005; Daly et al., 2007; Daily and Aquilante, 2009),
it could be speculated that the presence of defect CYP2C8 variant
alleles may influence the risk of developing colorectal cancer.
To date, only the effect of polymorphisms in CYP2C8 as mod-
ifiers of the protective effect of regular NSAID use has been ana-
lyzed. (McGreavey et al., 2005) In this study, CYP2C8 or CYP2C9
polymorphisms did not influence the protective effect of regular
NSAID use on the risk of colorectal cancer. Because CYP2C8 and
CYP2C9 polymorphisms show a great interethnic and intraethnic
variability (Martinez et al., 2006) and because positive association
of CYP2C9 genotypes with colorectal cancer risk was observed in
some populations (Bigler et al., 2001; Martinez et al., 2001; Tranah
et al., 2005; Hubner et al., 2006; Samowitz et al., 2006; Liao et al.,
2007; Cotterchio et al., 2008; Cross et al., 2008; Chan et al., 2009;
Siemes et al., 2009; Cleary et al., 2010) but not in other popula-
tions, and particularly in UK individuals (Sachse et al., 2002; Landi
et al., 2005; Hubner et al., 2006; Kury et al., 2007). It could be spec-
ulated that the association of low-penetrance genes with colorectal
cancer risk may vary from one population to another. Diet is a key
Table 2 | CYP2C8*1/*3 genotypes and allele frequencies in colorectal cancer patients and healthy controls.
Patients (n=153, 306 alleles) Controls (n=298, 596 alleles) OR (95% CI), p
GENOTYPES rs11572080 C/T (*1/*3)
CYP2C8*1/*1 111 (72.5; 65.5–79.6) 202 (67.8; 62.5–73.1) 1.26 (0.80–1.98), 0.299
CYP2C8*1/*3 36 (23.5; 16.8–30.3) 90 (30.2; 25.0–35.4) 0.71 (0.44–1.14), 0.135
CYP2C8*3/*3 6 (3.9; 0.8–7.0) 6 (2.0; 0.4–3.6) 1.99 (0.56–7.09), 0.233
ALLELE FREQUENCIES
CYP2C8*1 258 (84.3; 80.2–88.4) 494 (82.9; 79.9–85.9) 1.11 (0.75–1.64), 0.586
CYP2C8*3 48 (15.7; 11.6–19.8) 102 (17.1; 14.1–20.1) 0.90 (0.61–1.33), 0.586
The values in each cell represent: number (percentage) and [95% confidence intervals].
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Table 3 | CYP2C8*1/*3 genotypes of patients with colorectal cancer according to tumor site.
Non-sigmoid Sigmoid Rectum
GENOTYPES rs11572080 C/T (*1/*3)
CYP2C8*1/*1 39 (70.9; 58.9–82.9) 37 (77.1; 65.2–89.0) 35 (70.0; 57.3–82.7)
CYP2C8*1/*3 14 (25.5; 13.9–37.0) 9 (18.8; 7.7–29.8) 13 (26.0; 13.8–38.2)
CYP2C8*3/*3 2 (3.6; 0–8.6) 2 (4.2; 0–9.8) 2 (4.0; 0–9.4)
HAPLOTYPES
CYP2C8*1 92 (83.6; 76.7–90.5) 83 (86.5; 79.6–93.3) 83 (83.0; 75.6–90.4)
CYP2C8*3 18 (16.4; 9.5–23.3) 13 (13.5; 6.7–20.4) 17 (17.0; 9.6–24.4)
The values in each cell represent: number (percentage) and (95% confidence intervals).
factor in colorectal cancer risk, and because dietary determinants
of colorectal cancer may vary greatly in different geographic loca-
tions, the contribution of low-penetrance genes to the overall risk
may vary across populations.
For the above-mentioned reasons we decided to undertake the
study in a population in which a positive effect of CYP2C9 poly-
morphism in colorectal cancer risk had already been identified.
Because CYP2C9∗2 and CYP2C8∗3 variant alleles are at linkage
disequilibrium (Yasar et al., 2002; Martinez et al., 2005, 2007),
it could be expected that the association observed between the
CYP2C9 genotypes and colorectal cancer risk (Martinez et al.,
2001; Chan et al., 2004, 2009; Cleary et al., 2010; Northwood et al.,
2010), could be partly related to the presence of the CYP2C8∗3
variant allele. However, the findings obtained in the present study
indicate that no major association of the CYP2C8∗3 variant allele
and colorectal cancer risk is present in the population analyzed.
A limiting factor in this study is that no other defect
CYP2C8 alleles were analyzed. However, it should be empha-
sized that we tested for CYP2C8∗3 which is the most common
defect CYP2C8 allele in Caucasian individuals (see the website
http://www.cypalleles.ki.se/cyp2c8.htm), whereas other variant
alleles such as CYP2C8∗2, CYP2C8∗4, or CYP2C8∗5 are extremely
rare or no conclusive evidence for their deleterious effect on drug
metabolism in vivo is available, revised in (Martinez et al., 2006).
Another putative limiting factor in this study is the sample size.
It should however be emphasized that in the study population
the positive association of colorectal cancer risk with CYP2C9
genotype was identified with a smaller sample size (Martinez
et al., 2001) and hence, in the event that a major linkage between
CYP2C8∗3 and colorectal cancer risk might exist in the population
studied, the sample size would be enough to identify it. In con-
clusion, our findings, with sufficient statistical power to detect an
odds ratio equal to 1.6, indicate that the CYP2C8∗3 variant allele
does not show a major association with colorectal cancer risk.
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